StockData
Autolus Therapeutics plc logo

Autolus Therapeutics plc (AUTL) stock

AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3020% below fair value
$1.09−0.05 (-4.39%)

Close on Nov 17, 2026Market cap $290.12MP/E –Yield –

Earnings

Autolus Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 26, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$41.24M
+95.4% on a year earlier
EPS, Q3 FY2026
-$0.21
-$0.30 a year earlier
Latest guidance
Issued
Nov 10, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Autolus Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 26, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026before the open$41.24M+95.4%-$0.21Release
Q2 FY2026ended Jun 30, 2026Aug 11, 2026before the open$45.69M+118.6%-$0.15Release
Q1 FY2026ended Mar 31, 2026May 14, 2026before the open$26.20M+191.1%-$0.27Release
Q4 FY2025ended Dec 31, 2025Mar 27, 2026before the open$24.29M–-$0.34Release
Q3 FY2025ended Sep 30, 2025Nov 12, 2025before the open$21.10M–-$0.30Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025before the open$20.90M–-$0.18Release
Q1 FY2025ended Mar 31, 2025May 8, 2025before the open$9.00M-10.8%-$0.26Release
Q4 FY2024ended Dec 31, 2024Mar 20, 2025before the open–––Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024before the open––-$0.31Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024before the open––-$0.22Release
Q1 FY2024ended Mar 31, 2024May 17, 2024before the open$10.09M–-$0.24Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Autolus Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
AUCATZYL net product revenueFY2026$150.00M–NewNov 10, 2026
AUCATZYL net product revenueFY2026$140.00M – $150.00M$120.00M – $135.00MRaisedAug 11, 2026

Guidance history

Every forecast Autolus Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 10, 2026AUCATZYL net product revenueFY2026$150.00MNew
Aug 11, 2026AUCATZYL net product revenueFY2026$140.00M – $150.00MRaised
May 14, 2026AUCATZYL net product revenueFY2026$120.00M – $135.00MReaffirmed
Mar 27, 2026AUCATZYL net product revenueFY2026$120.00M – $135.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Autolus Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Update
  6. News
  7. News
  8. News
  9. Results
  10. Results
  11. Update
  12. Update
  13. Results
  14. Results
  15. Update

See a number that looks wrong?